CGuard EPS Carotid Stent Platform NSPR Nasdaq Investor Presentation

Inspira Technologies presents the CGuard EPS stent platform utilizing proprietary MicroNet technology for carotid artery disease treatment and stroke prevention. The company highlights nine completed clinical trials with over 1,850 patients, double-digit market share in 30+ countries, and FDA approval anticipated in H1 2025. With a $1.3 billion addressable market and 50,000+ stents already sold, CGuard aims to transform the carotid intervention market.